CNC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Centene Corp (CNC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown a recent price increase and has positive technical indicators, the financial performance is weak, with significant declines in net income, EPS, and gross margin. Additionally, mixed analyst ratings and a lack of strong positive catalysts suggest a cautious approach. Holding the stock or waiting for more clarity after the Q1 2026 financial results on April 28 is recommended.
The MACD histogram is positive at 0.73 and expanding, indicating bullish momentum. RSI is at 82.392, signaling the stock is overbought. Moving averages are converging, and the stock is trading near resistance levels (R2: 39.949). The stock has shown a 3.72% increase in regular market trading but is slightly down in pre-market (-0.35%).
The stock has shown a recent price increase of 3.72% in regular trading. Analysts have raised price targets in some cases, citing Medicare Advantage rate visibility and stable Medicaid margins. Health Net's $3 million investment in Sacramento may improve brand perception.
Financial performance in Q4 2025 was weak, with a significant drop in net income (-489.05% YoY) and EPS (-500.00% YoY). Analysts have mixed ratings, with some lowering price targets and citing concerns about Medicaid and health insurance exchange dis-enrollment. The stock is overbought based on RSI, and the next day/week stock trend suggests potential short-term declines.
In Q4 2025, revenue increased by 21.86% YoY to $49.725 billion. However, net income dropped significantly to -$1.101 billion (-489.05% YoY), EPS fell to -2.24 (-500.00% YoY), and gross margin decreased to 4.3% (-48.50% YoY).
Analysts are mixed on Centene. BofA raised the price target to $34 but maintained an Underperform rating. JPMorgan lowered the price target to $41 and kept a Neutral rating, citing near-term uncertainty. Goldman Sachs and Mizuho also lowered price targets, with concerns about Medicaid and exchange enrollment. Truist and Morgan Stanley have more optimistic views, raising price targets and highlighting margin opportunities and stable Medicaid margins.
